Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
Trial details
- Registry ID
- NCT03232567
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAXNCT03232567 | ALT | Phase 2 | Completed | 2018-03-07Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |